- Home
- LXEH vs IFRX Comparison
LXEH vs IFRX Comparison
Compare LXEH & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | IFRX |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | China | Germany |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 60.6M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LXEH | IFRX |
|---|---|---|
| Price | $0.23 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 556.7K | 171.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.71 |
| 52 Week High | $50.08 | $1.94 |
Technical Indicators
Market Signals| Indicator | LXEH | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 52.69 |
| Support Level | $0.19 | $0.75 |
| Resistance Level | $0.28 | $1.16 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 16.78 | 50.85 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.